1. Home
  2. GGR vs BNR Comparison

GGR vs BNR Comparison

Compare GGR & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gogoro Inc.

GGR

Gogoro Inc.

N/A

Current Price

$2.30

Market Cap

83.3M

ML Signal

N/A

Logo Burning Rock Biotech Limited

BNR

Burning Rock Biotech Limited

N/A

Current Price

$9.31

Market Cap

94.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GGR
BNR
Founded
2011
2014
Country
Taiwan
China
Employees
N/A
N/A
Industry
Auto Manufacturing
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
83.3M
94.4M
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
GGR
BNR
Price
$2.30
$9.31
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
14.9K
4.2K
Earning Date
05-21-2026
06-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$5.07
$111.65
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.29
$6.79
52 Week High
$6.21
$41.72

Technical Indicators

Market Signals
Indicator
GGR
BNR
Relative Strength Index (RSI) 29.72 53.93
Support Level N/A $8.69
Resistance Level $4.25 $10.00
Average True Range (ATR) 0.20 0.52
MACD -0.02 0.07
Stochastic Oscillator 10.42 50.58

Price Performance

Historical Comparison
GGR
BNR

About GGR Gogoro Inc.

Gogoro Inc is focused on eliminating the barriers to electric fuel adoption to bring swappable electric power within reach of every urban rider. Its battery swapping technology compromises an interoperable platform that seamlessly integrates a comprehensive ecosystem of hardware, software, and services, which consists of Gogoro Smart Batteries, GoStations, Gogoro Network Software & Battery Management Systems, Smartscooter, and related components and kits. Geographical presence in Taiwan and Other countries, majority of its revenue comes from Tiwan.

About BNR Burning Rock Biotech Limited

Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.

Share on Social Networks: